Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome
- First Online:
- 422 Downloads
Glucagonomas are slow-growing, rare pancreatic neuroendocrine tumors. They may present with paraneoplastic phenomena known together as the “glucagonoma syndrome.” A hallmark sign of this syndrome is a rash known as necrolytic migratory erythema (NME). In this paper, the authors describe a patient with NME and other features of the glucagonoma syndrome. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. Surgical and medical treatment options are reviewed. When detected early, a glucagonoma is surgically curable. It is therefore imperative that clinicians recognize the glucagonoma syndrome in order to make an accurate diagnosis and refer for treatment.
KEY WORDSglucagonoma neuroendocrine tumors necrolytic migratory erythema
- 14.Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. Medscape General Medicine. September 10, 2004 ed. Volume 6, 2004.Google Scholar
- 24.National Comprehensive Cancer Network (NCCN) guidelines. <http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#neuroendocrine>. Accessed March 14, 2013.
- 26.Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.PubMedCrossRefGoogle Scholar